Abstract:SMARCA4 (SWI/SNF-related, matrix-associated, actin dependent regulator of chromatin, subfamily A), an oncogene located at 19p13.2 and encodes the BRG1 protein, is one of the important subunits of SWI/SNF chromatin remodeling complex, which has been considered as a powerful regulator of transcription and DNA repairing, thereby plays an important role in cell cycle control and cell differentiation. [ 1 ] The inactivation of SMARCA4 protein usually leads to a loss of the function of the subunit in SWI/SNF complex and the interruption of ATP energy supply, thus affecting the repositioning or remodeling of the nucleosome of the complex. Transcription cannot be progressed due to the lacking of access to the DNA region that needs to be transcribed, and finally result in the occurrence and progression of various cancer types. [ 2–4 ] SMARCA4 is a novel oncogene that has been reported and named in recent years. In 2015, Le Loarer et al reported a type of highly aggressive thoracic sarcomas, which occurring in young male patients, along with undifferentiated immunophenotype and SMARCA4 loss, and usually presented as an extremely aggressive clinical course and named it as SMARCA4-deficient thoracic sarcoma. [ 5 ] In 2021, the new WHO Classification of Tumors of the Lung, Pleura, Thymus, and Heart adopted the term "SMARCA4-deficient undifferentiated tumor (SMARCA4-dUT)" for the group of tumors that has been previously described as SMARCA4-dTS, which is considered a separate entity from SMARCA4-deficient non-small cell lung cancer (NSCLC). [ 6 ] SMARCA4 mutations has been reported in a variety of cancer types, including uterine sarcoma, small cell carcinoma of the ovary with hypercalcemia, undifferentiated carcinoma of the nasal cavity/sinuses, pleomorphic carcinoma of the gastrointestinal tract, Burkitt lymphoma, and approximately 5% of NSCLC. [ 7 ] It has been reported that patients diagnosed as NSCLC harboring SMARCA4-deficient presented with the characteristics including absence of targetable sensitive mutations, primary resistant to various cytotoxic drugs, and thereby leading to poor prognosis. [ 8 , 9 ] The largest retrospective study which screened 2689 patients with NSCLC for SMARCA4 mutations, conducted in Dana-Farber Cancer Institute has reported that patients with SWI/SNF-mutant NSCLCs had a statistically lower prevalence of concurrent targetable driver mutations ( P < .001), and a significantly shorter median overall survival (mOS) from the time of advanced disease diagnosis ( P = .01), when comparing to SWI/SNF wild-type NSCLC. [ 10 ] Among the 555 SWI/SWF-mutated tumors in that research, the most frequently co-altered genes were presented as TP53, KRAS, and STK11.

SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers

Aurora kinase A inhibition induces synthetic lethality in SMAD4-deficient colorectal cancer cells via spindle assembly checkpoint activation

Clinical characteristics and prognostic analysis of patients with SMARCA4-deficient lung cancer

Aurora Kinase A Inhibition Potentiates Platinum and Radiation Cytotoxicity in Non-Small-Cell Lung Cancer Cells and Induces Expression of Alternative Immune Checkpoints

Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer

SMARCA4: Current status and future perspectives in non-small-cell lung cancer

The SMARCA4R1157W mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer

Inhibition of AURKB, regulated by pseudogene <i>MTND4P12</i>, confers synthetic lethality to PARP inhibition in skin cutaneous melanoma

The SMARCA4<SUP>R1157W</SUP> mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer

Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors.

The SMARCA4 R1157W mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer

Clinical features and prognostic biomarkers in patients with SMARCA4-mutated non-small cell lung cancer

BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency

A Critical Review of the Impact of SMARCA4 Mutations on Survival Outcomes in Non-Small Cell Lung Cancer

Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer

SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions

CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary

P1.02-059 Molecular Characteristics of SMARCA4 Mutations Detection in Chinese Non-Small Cell Lung Cancer Patients

Research Progress on SMARCA4 Mutation Non-small Cell Lung Cancer

Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer

Concurrent EGFR mutation and SMARCA4 deficiency in non-small cell lung cancer: A case report and literature review